89bio Inc

89bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded in January 2018 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Here is how 89BIO (ETNB) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.

Are Medical Stocks Lagging 89BIO (ETNB) This Year?

Akero Therapeutics Inc

Eli Lilly

Madrigal Pharmaceuticals

Novo Nordisk

Pfizer

Vertex Pharmaceuticals

Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in development that could become alternatives to popular injectables like Wegovy and Ozempic.

Weight-loss drugs in development aim to replace injections with pills

– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin's favorable safety and tolerability profile –

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints –

Data from 89bio's ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the stock with an outperform rating. The company is focused on developing pegozafermin as a treatment for cardio-metabolic and liver diseases, including non-alcoholic steatohepatitis (NASH), or inflammation caused by buildup of fat in the liver.

89bio shares rise as analysts see improved outlook for NASH treatments

SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that pegozafermin data in nonalcoholic steatohepatitis (NASH) will be featured in a late-breaker oral presentation during the European Association for the Study of the Liver (EASL) Congress 2023 to be held June 21-24, 2023 in Vienna, Austria. The presentation was selected for inclusion in the Best of EASL Congress summary slide deck that highlights the most noteworthy contributions to the scientific program at EASL.

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB crossed above the 20-day moving average, suggesting a short-term bullish trend.

89BIO (ETNB) Just Overtook the 20-Day Moving Average

ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now.

89bio: Great Prospects After Excellent Phase 2 Data

SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of ENTRUST, a Phase 3 trial evaluating the efficacy, safety and tolerability of pegozafermin in patients with severe hypertriglyceridemia (SHTG). "We are pleased to initiate the ENTRUST trial of pegozafermin in SHTG, an important milestone for the company that demonstrates the rapid progress we have made since inception, and also signifies entry of the first FGF21 analog into Phase 3 development,” said Hank Mansbach, Chief Medical Officer of 89bio.

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

The mean of analysts' price targets for 89BIO (ETNB) points to a 57.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know

– Positive topline results from ENLIVEN Phase 2b trial of pegozafermin in NASH demonstrated high statistical significance on both primary histology endpoints supporting advancement to Phase 3; discussions with regulatory agencies planned for the second half of 2023 –

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

SAN FRANCISCO, May 02, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company's Management will participate in the following upcoming conferences in May:

89bio to Participate in Upcoming Investor Conferences

Karuna Therapeutics Inc

Morphic Holding Inc

89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.

3 Biotech Buyout Targets to Watch

Here is how 89BIO (ETNB) and Henry Schein (HSIC) have performed compared to their sector so far this year.

Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year?

The mean of analysts' price targets for 89BIO (ETNB) points to a 79.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

Fintel reports that Ra Capital Management has filed a 13D/A form with the SEC disclosing ownership of 12.88MM shares of 89bio Inc (ETNB).

Ra Capital Management Now Owns 18% of 89bio

Intercept Pharma

Terns Pharmaceuticals

Viking Therapeutics

NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH

89bio announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25 The post 89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering appeared first on Pulse 2.0.

89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering

89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH drug has been approved yet by the FDA.

Why Shares of 89bio Soared This Week

89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The company said it sold 16.92 million common shares at $16.25 each, to raise $275.0 million.

89bio's public stock offering upsized by 38%, priced at a 4% discount

SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25. In addition, 89bio has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,538,461 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $275 million. The offering is expected to close on or about March 28, 2023, subject to the satisfaction of customary closing conditions.

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.

89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study

SAN FRANCISCO, March 22, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $30 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio.

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

The shares of 89bio Inc   ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biotech name revealed its experimental drug pegozafermin to treat nonalcoholic steatohepatitis (NASH) -- a type of fatty liver disease -- met the main objectives of a mid-stage study.

Biotech Stock Surges on Mid-Stage Drug Trial Success

89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial. The goal of this study is to determine the effectiveness of pegozafermin in treating patients with NASH.

News for 89bio Inc Stock (ETNB)